Business
Cannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies
Cannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nCannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nCannabics Pharmaceuticals Announces Publication of Clinical Data From Its Sponsored Pilot Study on Controlled Release Capsules, on the Journal of Integrative Cancer Therapies\nData Demonstrated Cannabics' SR capsules with 5 mg dosage seems to be appropriate for the treatment of cancer anorexia-cachexia syndrome (CACS) in advanced cancer patients under active treatment.\nPR Newswire\nTEL AVIV, Israel and BETHESDA, Maryland, Oct. 16, 2019\n\n\n\nTEL AVIV, Israel and BETHESDA, Maryland, Oct. 16, 2019 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the final results of its pilot study to test the efficacy of Cannabics' Dosage-Controlled capsules for the treatment of cancer anorexia-cachexia syndrome (CACS) in advanced cancer patients have been published on the Journal of Integrative Cancer Therapies. \n\n \n \n\n \nThe study was performed at the Rambam Health Care Campus (HCC), Division of Oncology, in Haifa, Israel, and led by Dr. Gil Bar Sela (MD). The study objective was to evaluate the effect of dosage-controlled cannabis capsules on CACS in advanced cancer patients, and more specifically, on patient weight variation. \nInclusion criteria comprised: age older than 18 years, histological evidence of an incurable malignancy, estimated life expectancy ≥3 months, performance status ≤3 (ECOG [Eastern Cooperative Oncology Group]) classification, weight loss of at least 5% during the preceding 2 months (as documented in the patient's medical file), and the patient's belief that loss of appetite or weight loss is an ongoing problem for him/her. The use of chemotherapy or radiotherapy was allowed.\nThe study protocol was approved by the Ministry of Health Unit for Medical Cannabis and by the hospital's institutio...